| Identification | Back Directory | [Name]
Imirestat | [CAS]
89391-50-4 | [Synonyms]
AL-1576
HOE-843
Imirestat
Alcon 1576
2,7-Difluorospiro[Fluorene-9,4'-IMidazolidine]-2',5'-Dione
2,7-Difluorospiro[9H-fluorene-9,4'-imidazolidine]-2',5'-dione
Spiro[9H-fluorene-9,4'-imidazolidine]-2',5'-dione, 2,7-difluoro-
2,7-Difluoro-2'H,5'H-spiro[fluorene-9,4'-imidazolidine]-2',5'-dione | [Molecular Formula]
C15H8F2N2O2 | [MDL Number]
MFCD00865639 | [MOL File]
89391-50-4.mol | [Molecular Weight]
286.23 |
| Chemical Properties | Back Directory | [density ]
1.58±0.1 g/cm3(Predicted) | [solubility ]
DMSO: Soluble: =10 mg/ml | [form ]
Solid | [pka]
8.17±0.20(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
Imirestat (AL 1576) is an aldose reductase inhibitor, used for the treatment of diabetes. | [in vivo]
Imirestat (1 mg/kg) improves nerve conduction velocity but is without effect upon the resistance to hypoxic conduction blockade or the deficit in insulin-stimulated oubain-sensitive ATPase activity[1]. | [References]
[1] Carrington AL, et al. Aldose reductase inhibition with imirestat-effects on impulse conduction and insulin-stimulation of Na+/K(+)-adenosine triphosphatase activity in sciatic nerves of streptozotocin-diabetic rats. Diabetologia. 1991 Jun;34(6):397-401. DOI:10.1007/BF00403177 |
|
|